Suppr超能文献

胰岛素百年史:胰岛素为何如此昂贵,以及有哪些控制其成本的措施?

100 years of Insulin: Why is Insulin So Expensive and What Can be Done to Control Its Cost?

机构信息

Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan Medical School, 1000 Wall Street, Brehm Tower, Room 6108, Ann Arbor, MI 48105, USA; Department of Epidemiology, University of Michigan School of Public Health, 1000 Wall Street, Brehm Tower, Room 6115, Ann Arbor, MI 48105, USA.

Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan Medical School, 1000 Wall Street, Brehm Tower, Room 6108, Ann Arbor, MI 48105, USA.

出版信息

Endocrinol Metab Clin North Am. 2021 Sep;50(3S):e21-e34. doi: 10.1016/j.ecl.2021.09.001. Epub 2021 Oct 14.

Abstract

The discovery of insulin 100 years ago and subsequent improvements in insulin formulations and delivery devices have changed the lives of people with diabetes. Unfortunately, the average price of insulin in the United States has nearly tripled over the past decade, and the high cost of insulin has become a barrier to diabetes treatment. On the 100th anniversary of insulin's discovery, this life-saving treatment is financially out of reach for as many as one-third of people with diabetes. The challenge now is to ensure that insulin is available for all people with diabetes who need it. We explore reasons for the high cost of insulin and recommend some clinical and policy interventions to improve insulin access and affordability.

摘要

胰岛素发现 100 年来,胰岛素制剂和给药装置的不断改进改变了糖尿病患者的生活。遗憾的是,过去十年间,美国胰岛素的平均价格几乎翻了三倍,而胰岛素的高昂费用已成为糖尿病治疗的障碍。在胰岛素发现 100 周年之际,多达三分之一的糖尿病患者因经济原因无法获得这种救命治疗。当前的挑战是确保所有有需要的糖尿病患者都能获得胰岛素。我们探讨了胰岛素价格居高不下的原因,并提出了一些改善胰岛素可及性和可负担性的临床和政策干预措施。

相似文献

1
100 years of Insulin: Why is Insulin So Expensive and What Can be Done to Control Its Cost?
Endocrinol Metab Clin North Am. 2021 Sep;50(3S):e21-e34. doi: 10.1016/j.ecl.2021.09.001. Epub 2021 Oct 14.
2
The impact of biosimilar insulins on the diabetes landscape.
J Manag Care Spec Pharm. 2022 Jan;28(1):91-98. doi: 10.18553/jmcp.2021.21253. Epub 2021 Nov 2.
4
Addressing Insulin Access and Affordability: An Endocrine Society Position Statement.
J Clin Endocrinol Metab. 2021 Mar 25;106(4):935-941. doi: 10.1210/clinem/dgaa817.
5
The Noble and Often Nobel Role Played by Insulin-Focused Research in Modern Medicine.
Diabetes Care. 2022 Jan 1;45(1):23-27. doi: 10.2337/dci21-0012.
6
Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?
Curr Diab Rep. 2017 Sep;17(9):71. doi: 10.1007/s11892-017-0893-0.
7
[Evolution of insulin therapy: past, present, future].
Probl Endokrinol (Mosk). 2024 Jan 24;69(6):86-101. doi: 10.14341/probl13251.
8
New ways of insulin delivery.
Int J Clin Pract Suppl. 2010 Feb(166):29-40. doi: 10.1111/j.1742-1241.2009.02276.x.
9
Looking beyond the issue of access to insulin: what is needed for proper diabetes care in resource poor settings.
Diabetes Res Clin Pract. 2010 Jun;88(3):217-21. doi: 10.1016/j.diabres.2010.03.029. Epub 2010 May 5.
10
The discovery of insulin revisited: lessons for the modern era.
J Clin Invest. 2021 Jan 4;131(1). doi: 10.1172/JCI142239.

引用本文的文献

2
Effects of the Part D Senior Savings Model on racial and ethnic disparities in healthcare costs.
Curr Med Res Opin. 2025 Mar;41(3):431-440. doi: 10.1080/03007995.2025.2479780. Epub 2025 Mar 31.
4
Burden of Disease in Refugee Patients with Diabetes on the Island of Lesvos-The Experience of a Frontline General Hospital.
Int J Environ Res Public Health. 2024 Jun 25;21(7):828. doi: 10.3390/ijerph21070828.
7
Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?
J Clin Endocrinol Metab. 2024 Apr 19;109(5):e1379-e1388. doi: 10.1210/clinem/dgad610.
8
Economic burden, financial stress, and cost-related coping among people with uncontrolled diabetes in the U.S.
Prev Med Rep. 2023 May 15;34:102246. doi: 10.1016/j.pmedr.2023.102246. eCollection 2023 Aug.

本文引用的文献

1
National Trends in Out-of-Pocket Costs Among U.S. Adults With Diabetes Aged 18-64 Years: 2001-2017.
Diabetes Care. 2021 Nov;44(11):2510-2517. doi: 10.2337/dc20-2833. Epub 2021 Aug 24.
2
Costs and underuse of insulin and diabetes supplies: Findings from the 2020 T1International cross-sectional web-based survey.
Diabetes Res Clin Pract. 2021 Sep;179:108996. doi: 10.1016/j.diabres.2021.108996. Epub 2021 Aug 4.
4
One Hundred Years of Insulin for Some.
N Engl J Med. 2021 Jul 22;385(4):293-295. doi: 10.1056/NEJMp2105697. Epub 2021 Jul 17.
5
Living with Insulin: The story of insulin from people with diabetes.
Diabetes Res Clin Pract. 2021 Jun;176:108857. doi: 10.1016/j.diabres.2021.108857. Epub 2021 May 7.
6
The future of insulin therapy.
Diabetes Res Clin Pract. 2021 May;175:108820. doi: 10.1016/j.diabres.2021.108820. Epub 2021 Apr 16.
7
The evolution of insulin therapy.
Diabetes Res Clin Pract. 2021 May;175:108816. doi: 10.1016/j.diabres.2021.108816. Epub 2021 Apr 20.
8
In Brief: Semglee - a new insulin glargine for diabetes.
Med Lett Drugs Ther. 2021 Jan 25;63(1616):14-15.
9
A global perspective on the issue of access to insulin.
Diabetologia. 2021 May;64(5):954-962. doi: 10.1007/s00125-020-05375-2. Epub 2021 Jan 23.
10
Insulin's centenary: the birth of an idea.
Lancet Diabetes Endocrinol. 2020 Dec;8(12):971-977. doi: 10.1016/S2213-8587(20)30337-5. Epub 2020 Oct 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验